Myriam Di Penta

Real-world effectiveness and drug retention rate of risankizumab in patients with psoriatic arthritis: data from the multicentre GIRRCS cohort

Introduction Psoriatic arthritis (PsA) is a chronic heterogenous inflammatory disease characterized by a multidomain burden. Risankizumab, a selective inhibitor of the IL-23 p19 subunit, has shown efficacy in randomized trials; however, real-world data in PsA remain limited. We e...